July eFactor
Birnbaum headlines Detroit Community Forum
Leaders address Association of Public Health Laboratories
NIEHS spurs investigation into the health effects of e-waste recycling
Scholars Connect program welcomes class of 2013-2014
Agencies award $100,000 to winner of health and technology challenge
Office of Scientific Information Management takes shape
NIEHS launches website redesigned for mobile devices
WETP workshop identifies strategies to promote effective safety cultures
Former postdoc named chief research officer for NIH research partner
NIEHS brings public health perspective to climate change policy for...
Source: Environmental Factor - NIEHS Newsletter - July 9, 2013 Category: Environmental Health Source Type: news
How to survive the shortage of injectable sodium bicarbonate
Sodium bicarbonate is probably the most versatile antidote in the medical toxicologist’s armamentarium. The list of poisons for which bicarb is indicated lincludes:
Sodium-channel blockers (including tricyclic antidepressants)
Salicylates
phenobarbital
methotrexate
ethylene glycol
methanol
chlorine gas inhalation
It is, therefore, distressing that bicarb is among the many pharmaceuticals that have recently been in short supply. To read my Emergency Medicine News column on this problem — and find out what to do when sodium bicarbonate is simply not available, click here. (Source: The Poison Review)
Source: The Poison Review - July 9, 2013 Category: Toxicology Authors: Leon Tags: Medical drug shortage Emergency Medicine News sodium bicarbonate toxicology rounds Source Type: news
Prolonged toxic coma and anisocoria secondary to doxepin, lorazepam and phenobarbital poisoning--case study - Kołodziej M, Majewska M, Krajewska A, Szponar J.
Doxepin is a tricyclic antidepressant from the group of dibenzoxepines. Apart from the antidepressant effect, it has also the sedative and anxiolytic effect, so it is used in the treatment of anxiety disorder in the course of psychosis, organic diseases an... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - June 26, 2013 Category: Global & Universal Tags: Poisoning Source Type: news
UK firm halts sale of convulsion drug to Arkansas over death row use
UK-based pharmaceutical company Hikma has stopped supplying convulsion drug phenobarbital to Arkansas in the US to prevent it being used in state executions. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 16, 2013 Category: Pharmaceuticals Source Type: news
British maker of death penalty drugs adds new restrictions for US buyers
Hikma Pharmaceuticals moves to avoid 'unintended purposes' for drugs amid growing European boycott on sale to the USA drug manufacturer based in Britain has vowed to add new restrictions to sales of its products in the US after it was revealed that it sold a batch of barbiturate to the Arkansas department of corrections, which intended to use it in executions.Hikma Pharmaceuticals has promised to put in place "concrete steps to restrict the supply of its products for unintended uses" following the disclosure by the legal action charity Reprieve that a wholly owned subsidiary in the US had sold injectable phenobarbital to t...
Source: Guardian Unlimited Science - May 15, 2013 Category: Science Authors: Ed Pilkington Tags: United States Capital punishment World news Pharmaceuticals industry guardian.co.uk Europe Drugs UK news Arkansas Source Type: news
[Perspective] Old Dance with a New Partner: EGF Receptor as the Phenobarbital Receptor Mediating Cyp2B Expression
The direct interaction of phenobarbital with the epidermal growth factor receptor reveals a new network interface in nuclear receptor signaling. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 12, 2013 Category: Science Authors: Sharon A. Meyer, Randy L. Jirtle Source Type: news
[Research Article] Phenobarbital Indirectly Activates the Constitutive Active Androstane Receptor (CAR) by Inhibition of Epidermal Growth Factor Receptor Signaling
The epidermal growth factor receptor is an unexpected target of the barbiturate phenobarbital. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 7, 2013 Category: Science Authors: Shingo Mutoh, Mack Sobhany, Rick Moore, Lalith Perera, Lee Pedersen, Tatsuya Sueyoshi, Masahiko Negishi Source Type: news
What Causes Constipation?
Discussion
Constipation generally is defined as infrequent or painful defecation. Constipation can be very disturbing to the patient and family who believe the stools are too infrequent, too hard or too difficult to pass. Most children develop constipation after the child begins to associate pain (e.g. a hard bowel movement) with defecation. The child then begins to withhold the stools trying to decrease the defecation discomfort. As stool withholding continues, the rectum dilates and gradually accommodates with the normal defecation urge disappearing. Passing large hard stools infrequently reinforces the defecation pain. ...
Source: PediatricEducation.org - February 25, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news
What enhanced elimination techniques are useful in critical toxicology patients?
3 out of 5 stars
Enhanced Poison Elimination in Critical Care. Ghannoum M, Gosselin S. Adv Chronic Kidney Dis 2013 Jan;20:94-101.
Abstract
This survey of methods available for enhanced elimination in toxicology cases gives a good overview, but unnecessarily wastes time discussing modalities that now are never used (e.g., forced diuresis and urine acidification). The information would have been more accessible if it had been streamlined to reflect current practice. For instance, the authors list 20 poisons “amenable” to multidose activated charcoal, but in fact the indications for this treatment are limited and...
Source: The Poison Review - February 17, 2013 Category: Toxicology Authors: Leon Tags: Medical critical care enhanced elimination hemodialysis multidose activated charcoal overdose poisoning toxicology Source Type: news
FDA Updates Atazanavir Sulfate Capsule Labeling
“Recently [February 4, 2013] FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes.
“Section 5 Warnings and Precautions was revised to include cholelithiasis ...
“In section 6 Adverse Reactions: Postmarketing Experience, interstitial nephritis was added.
“In section 7 Drug Interactions: information regarding coadministration with boceprevir, carbamazepine, phenytoin, phenobarbital, lamotrigine and voriconazole was added.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press rele...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 12, 2013 Category: Infectious Diseases Source Type: news
